Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 2009

View Archived Issues

Novel inhibitors of MDM2 and p53 interaction claimed by Janssen Pharmaceutica

GlaxoSmithKline claims quinoxaline derivatives as PI3 kinase inhibitors

Novel androgen receptor agonists developed by Takeda

Novel non-nucleoside reverse transcriptase inhibitors claimed by GlaxoSmithKline

Organon claims TRVP1 modulators for treatment of pain

Schering-Plough presents novel alpha2C adrenoreceptor agonists

Vertex recaps year's events

AFFIRM data show high rate of relapsing-remitting multiple sclerosis remission with natalizumab

Mymetics to acquire Virosome Biologicals and expand vaccine portfolio

EC designates KNS-760704 as orphan medicinal product for ALS

Avexa and Progen terminate proposed merger agreement

GlaxoSmithKline identifies a novel EP1 receptor antagonist for the treatment of inflammatory pain

Mepact receives E.U. approval for non-metastatic resectable osteosarcoma

AVEO initiates phase Ib/IIa trial for AV-951 in non-small cell lung cancer

FDA grants orphan drug designation to Eurand's EUR-1073 for ulcerative colitis

Raloxifene does not affect the incidence of coronary events in postmenopausal women

Identification of the CR-6261 epitope may help rational vaccine design for influenza A

Generex Biotechnology presents successful phase III data for Generex Oral-lyn

Intra-Cellular Therapies reports final results for phase II ITI-007 trial

Solasia initiates clinical development of its first drug in Japan

Synosia enters second agreement with Roche for new-generation 5-HT6 antagonist

NCI to conduct in vitro and in vivo studies of Azaya's cancer drug ATI-1123

Sunesis sells LFA-1 inhibitor program to SARcode for USD 2 million

Tolerx initiates enrollment in phase III DEFEND trial of otelixizumab in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...